Growth Hormone Dose Modulation and Final Height in Short Children Born Small for Gestational Age: French Real-Life Data
Authors' conclusion
GH therapy was fairly effective in most short children born SGA. No new safety concerns were identified.
Study context
- Population
- Short children born small for gestational age (SGA) treated with growth hormone (GH) at 126 sites in France, followed >5 years until final adult height (FAH) or study terminationof 1,408 registered
- Participants
- 291 children
- Outcome
- Proportion of patients with normal (>−2) height SDS at last visit and with normal FAH SDS
- Follow-up
- Last visit
Methodological detailsmulticentre, real-world, post hoc multivariate logistic regression analyses
- Multicentre
- Real-world
- Post hoc multivariate logistic regression analyses
Main finding
As reported in the abstract
Normal height standard deviation score (SDS) at last visit
193 of 291
66.3%
Reached FAH
72 of 291
24.7%
FAH SDS >−2 for chronological age
48
66.7%
FAH SDS >−2 for adult age
40
55.6%
Observational data: associations, not effects.
Further findings
- Height SDS at last visit was a significant determinant of GH dose modulation
- Normal height SDS associated with taller baseline height SDS, younger age at start, longer treatment duration (excluding discontinuations), and absence of chronic disease
- Post hoc analyses
Safety
- Non-serious adverse events
- 70%
- Adverse events possibly/probably related to GH
- 39%
Original publication
Growth Hormone Dose Modulation and Final Height in Short Children Born Small for Gestational Age: French Real-Life Data. Horm Res Paediatr. Published 11 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →